More cases, doctor? Yes please! by Jefferson, Tom
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Cases Journal
Open Access Editorial
More cases, doctor? Yes please!
Tom Jefferson
Address: Cochrane Vaccines Field, Anguillara Sabazia, Roma 00061, Italy
Email: Tom Jefferson - Jefferson.tom@gmail.com
The scientific basis of modern clinical practice is founded
on the randomised controlled trial [1]. Trials are experi-
mental studies in which two or more selected groups
(arms) which may (or may not be) "representative"of the
whole population are assigned at random to one or more
interventions and sometimes to an inert control (placebo)
or compared to standard practice. The idea is that ran-
domisation, if correctly applied to sufficient numbers
would spread the effect of confounders equally across all
arms of the trial. Randomisation creates the ultimate
experimental conditions: whatever differences I observe
between arms must be due to the only remaining modifi-
ying factor, i.e. the intervention. This could be a drug, a
diagnostic test, a vaccine or even an administrative proce-
dure or clinical pathway. Trials are needed for the registra-
tion of new drugs, vaccines and major procedures,
although curiously they are not necessary to register com-
monly used devices such as hip or knee prostheses. As a
consequence of the importance of trials a whole new
branch of epidemiology (let's call it trialology) was born
to study trials, their design, conduct, reporting, synthesis
and the implementation of their findings [2-4].
However, in addition to some very notorious woes (pub-
lication and reporting bias, piecemeal or redundant pub-
lication, spin or faking of results) trial results are seen by
some practicing clinicians as being of limited relevance to
their everyday practice as they embody a population-
based approach to healthcare. This approach seems at
odds with everyday experience in one's surgery, depart-
ment or emergency room [5]. The typical participant of a
trial is described in a synthetic fashion (because of report-
ing standards and space constraint in journals) and often
does not seem to quite fit the patient we have in front of
us or the context we work in. Statements such as "if you
take wondermycin three times a day for five days with
food you have a 75% chance of feeling better by the end
of the course" are sometimes difficult to grasp and discuss.
Over 70% of physicians' information needs are about
diagnosis and/or treatment and over 60% of these are
foreground (i.e. relating to the patient they have in front)
[5]. Crucially, the time devoted to the search for the infor-
mation cannot take more than 2 minutes, especially in
those health systems such as the British NHS in which
consultation lenght is around 7–10 minutes [6].
In reality the biggest problem with trials is their inductive
basis. Induction was first systematized by Francis Bacon
(1561 – 1626) in his "Novum Organum". Induction is the
process by which after repeated observations leading to
the same conclusions I make a generalised statement
which forms the basis of knowledge and sometimes links
cause and effect. For example if I get into my car every
morning and turn the ignition key and the engine starts
every time, I soon conclude (wrongly) that the motion of
turning the key is inexorably linked to the engine starting
up. However if my battery is flat, the starter motor is bro-
ken or the engine is blown because of my lack of care the
cause and effect link is broken. Equally, in a well-con-
ducted trial I induce that whatever I have observed in my
carefully collected sample of participants will also happen
in all similar people across the planet. Here I have two lev-
els of generalisation: a first level from my sample to the
whole population (this is called abstraction). The second
level (analytical generalisation) is when I generalise from
experimental findings to theory [7,8]. This idea is based
on the concept of the uniformity of nature which the scot-
tish philosopher David Hume (1711 – 1776) correctly
pointed out as simply non-existant ("An universal state-
ment asserting the validity of the principle of induction is
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here inferred from a number of singular observation state-
ments. Thus this argument is inductive. This is "the prob-
lem of induction") [9]. In other words the general
statement on the likely effects of wondermycin is justifed
by past and current perfomance of wondermycin. This is
induction justifying itself. The problem of induction has
been only partly addressed by the use of statistical proba-
bilism, as embodied in the hypothetical statement on
wondermycin already quoted. In reality, despite our use
of probability theory and all its paraphernalia of curves,
tests and confidence intervals the problem of induction
remains. No two patients are alike and no two sets of cir-
cumstances are absolutely similar. This is why trials and
all other population-based studies, even if we had the
whole picture of wondermycin perfomance (which we
know is very unlikely, especially for new drugs) can only
give us a very broad steer in our eveyday practice [10]. The
great mathematician-philospher turned peace campaigner
Bertrand Russel (1872 – 1970) mocked induction and its
limits with his famous story of the inductivist turkey
[11,12].
"The turkey found that, on his first morning at the turkey
farm, that he was fed at 9 a.m. Being a good inductivist
turkey he did not jump to conclusions. He waited until he
collected a large number of observations that he was fed
at 9 a.m. and made these observations under a wide range
of circumstances, on Wednesdays, on Thursdays, on cold
days, on warm days. Each day he added another observa-
tion statement to his list. Finally he was satisfied that he
had collected a number of observation statements to
inductively infer that "I am always fed at 9 a.m.". However
on the morning of Christmas Eve he was not fed but
instead had his throat cut.
Thus the inductivist turkey ended in the pot.
If we cannot rely (at least completely) on trials to give use
guidance in everyday life can we then rely on non-ran-
domised studies? After all, these formal studies are
thought to take place in conditions which are closer to
everyday life. Anyone who has critically appraised large
numbers of these studies knows that reporting and design
problems are even worse than in trials. Is anyone not con-
vinced by this statement? Take a second look at the last
five case-control studies you have read. How many of
these specified that the choice and analysis of cases and
controls was done by a researcher blind to exposure status
of both? This is an absolute pre-requisite in any case con-
trol study to minimise the risk of observer bias. Some of
the international efforts to minimise the risk of publica-
tion bias of trials (such as the introduction of prospective
registration) have never even been mentioned for non-
randomised studies. In addition the problem of induction
(which is still present in these studies) is made worse by
the murky play of confounders. The late Professor Geof-
frey Rose used to repeat the aphorism that you can adjust
for the confounders you know or guess at, not for the ones
you do not know.
So how can we get some guidance for our patient action
plan which is more likely to be predictive than a wonder-
mycin registration trial of what will actually happen to our
patient once I give him or her the drug [12]?
The obvious answer seems to me to be other people's
practical experience embodied in case reports. Up to now
case reports have been considered a backwater for old
fogies and experts of the exotic. However, reports of every-
day problems and solutions are more likely than anything
else in biomedical science to approximate and recreate the
conditions we are in. Remember: Florey first demon-
strated the effects of penicillin on a case series of 8. My
statement on the use of case reports has two provisos.
First, cases need to be available in huge numbers to be
likely to inform our actions in the millions of different sit-
uations of everyday clinical practice. This collection
should be seen as an udertaking to rival the human
genome project or the setting up and development of the
Cochrane Collaboration. As the latter, it should be an
open ended effort.
Second, the casebook (which is more likely to end up rep-
resenting a casebank) needs to be housed in an easily
accessible virtual building and the search facilities need to
reflect the time-constraints of everyday life. A statement
such as "Excuse me madam or sir, would you mind wait-
ing outside for 3 hours while I search the net for a case
similar to yours?" would not be very popular with busy
practioners or bewildered patients. A variety of search
engines can be constructed some even using revolutionary
methods as self-organising maps (a method taken from
neural network theory).
Both these provisos entail effort, standardisation of
reporting formats and commitment of ever increasing
numbers of practioners and perhaps patients. However,
think of the practical benefits. What if we could access the
case book of William Osler or even of my old family doc-
tor who died 20 years ago? How many lessons would we
learn or re-learn? Let's transform this vision into a reality.
What better challenge can there be for a new journal?
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